NASDAQ:BLCM - Bellicum Pharmaceuticals Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $3.62 +0.05 (+1.40 %) (As of 03/26/2019 10:30 AM ET)Previous Close$3.57Today's Range$3.59 - $3.6652-Week Range$2.74 - $10.26Volume503 shsAverage Volume419,036 shsMarket Capitalization$160.44 millionP/E Ratio-1.47Dividend YieldN/ABeta1.56 ProfileDiscussionAnalyst RatingsChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Bellicum Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on discovering and developing novel cellular immunotherapies for the treatment of hematological cancers, solid tumors, and orphan inherited blood disorders in the United States and internationally. The company's clinical product candidates include BPX-501, an adjunct T cell therapy in multiple Phase I/II clinical trials, administered after allogeneic hematopoietic stem cell transplantation; and BPX-601, a GoCAR-T product candidate in Phase I clinical trial for treating solid tumors expressing the prostate stem cell antigen. Its clinical product candidates also comprise BPX-701, a T cell receptors (TCR) based therapy in Phase I clinical trial for the treatment of malignant cells expressing the preferentially-expressed antigen in melanoma; and CD19, a chimeric antigen receptor T cell therapy for expressing B cell malignancies setting. It has collaboration agreements with Adaptimmune Therapeutics plc to evaluate, develop, and commercialize T cell therapies; and Academisch Ziekenhuis Leiden for research to discover and validate high-affinity TCR product candidates targeting various cancer-associated antigens. Bellicum Pharmaceuticals, Inc. was founded in 2004 and is headquartered in Houston, Texas. Receive BLCM News and Ratings via Email Sign-up to receive the latest news and ratings for BLCM and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:BLCM Previous Symbol CUSIPN/A CIK1358403 Webwww.bellicum.com Phone832-384-1100Debt Debt-to-Equity Ratio0.52 Current Ratio6.03 Quick Ratio6.03Price-To-Earnings Trailing P/E Ratio-1.47 Forward P/E Ratio-1.73 P/E GrowthN/A Sales & Book Value Annual Sales$1.12 million Price / Sales143.25 Cash FlowN/A Price / Cash FlowN/A Book Value$1.58 per share Price / Book2.29Profitability EPS (Most Recent Fiscal Year)($2.44) Net Income$-98,040,000.00 Net Margins-8,753.21% Return on Equity-115.46% Return on Assets-72.05%Miscellaneous Employees173 Outstanding Shares44,320,000Market Cap$160.44 million Next Earnings Date5/14/2019 (Estimated) OptionableOptionable Bellicum Pharmaceuticals (NASDAQ:BLCM) Frequently Asked Questions What is Bellicum Pharmaceuticals' stock symbol? Bellicum Pharmaceuticals trades on the NASDAQ under the ticker symbol "BLCM." How were Bellicum Pharmaceuticals' earnings last quarter? Bellicum Pharmaceuticals Inc (NASDAQ:BLCM) issued its earnings results on Tuesday, March, 12th. The biopharmaceutical company reported ($0.63) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($0.58) by $0.05. The biopharmaceutical company earned $0.31 million during the quarter, compared to analysts' expectations of $0.18 million. Bellicum Pharmaceuticals had a negative return on equity of 115.46% and a negative net margin of 8,753.21%. View Bellicum Pharmaceuticals' Earnings History. When is Bellicum Pharmaceuticals' next earnings date? Bellicum Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Tuesday, May 14th 2019. View Earnings Estimates for Bellicum Pharmaceuticals. What price target have analysts set for BLCM? 3 brokerages have issued twelve-month price objectives for Bellicum Pharmaceuticals' shares. Their predictions range from $6.85 to $19.00. On average, they expect Bellicum Pharmaceuticals' stock price to reach $14.6167 in the next twelve months. This suggests a possible upside of 304.9% from the stock's current price. View Analyst Price Targets for Bellicum Pharmaceuticals. What is the consensus analysts' recommendation for Bellicum Pharmaceuticals? 3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Bellicum Pharmaceuticals in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Bellicum Pharmaceuticals. Has Bellicum Pharmaceuticals been receiving favorable news coverage? News stories about BLCM stock have been trending somewhat negative this week, according to InfoTrie Sentiment. The research group identifies negative and positive press coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. Bellicum Pharmaceuticals earned a coverage optimism score of -1.4 on InfoTrie's scale. They also assigned news headlines about the biopharmaceutical company a news buzz of 10.0 out of 10, meaning that recent press coverage is extremely likely to have an effect on the company's share price in the near future. Who are some of Bellicum Pharmaceuticals' key competitors? Some companies that are related to Bellicum Pharmaceuticals include TG Therapeutics (TGTX), Synthorx (THOR), DiaMedica Therapeutics (DMCAF), ChemoCentryx (CCXI), Aurinia Pharmaceuticals (AUPH), Viking Therapeutics (VKTX), Kura Oncology (KURA), NuCana (NCNA), Obseva (OBSV), Evolus (EOLS), ProQR Therapeutics (PRQR), Crinetics Pharmaceuticals (CRNX), Odonate Therapeutics (ODT), GlycoMimetics (GLYC) and G1 Therapeutics (GTHX). What other stocks do shareholders of Bellicum Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Bellicum Pharmaceuticals investors own include Gilead Sciences (GILD), ACADIA Pharmaceuticals (ACAD), Celgene (CELG), NVIDIA (NVDA), Exelixis (EXEL), Verastem (VSTM), Sangamo Therapeutics (SGMO), Synergy Pharmaceuticals (SGYP), bluebird bio (BLUE) and Editas Medicine (EDIT). Who are Bellicum Pharmaceuticals' key executives? Bellicum Pharmaceuticals' management team includes the folowing people: Mr. Richard A. Fair, Pres, CEO & Director (Age 50)Dr. Alan K. Smith, Exec. VP of Technical Operations (Age 61)Mr. Thomas J. Farrell, Consultant (Age 56)Mr. Atabak Mokari, Chief Financial Officer (Age 42)Ms. Rosemary Y. Williams, Interim Principal Accounting Officer, VP of Fin. & Controller When did Bellicum Pharmaceuticals IPO? (BLCM) raised $101 million in an IPO on Thursday, December 18th 2014. The company issued 6,300,000 shares at $15.00-$17.00 per share. Jefferies, Citigroup and Piper Jaffray acted as the underwriters for the IPO and Trout Capital was co-manager. Who are Bellicum Pharmaceuticals' major shareholders? Bellicum Pharmaceuticals' stock is owned by a number of of retail and institutional investors. Top institutional investors include BlackRock Inc. (6.77%), FMR LLC (1.77%), Geode Capital Management LLC (1.17%), Geode Capital Management LLC (1.17%), Northern Trust Corp (1.08%) and Millennium Management LLC (0.87%). Company insiders that own Bellicum Pharmaceuticals stock include Alan A Musso, Alan K Smith, Bros Advisors Lp Baker, David M Spencer, Jon P Stonehouse and Ken Moseley. View Institutional Ownership Trends for Bellicum Pharmaceuticals. Which major investors are selling Bellicum Pharmaceuticals stock? BLCM stock was sold by a variety of institutional investors in the last quarter, including BlackRock Inc., FMR LLC, Millennium Management LLC, Creative Planning, Northern Trust Corp, Virtu Financial LLC and Mcdaniel Terry & Co.. Company insiders that have sold Bellicum Pharmaceuticals company stock in the last year include Alan A Musso and David M Spencer. View Insider Buying and Selling for Bellicum Pharmaceuticals. Which major investors are buying Bellicum Pharmaceuticals stock? BLCM stock was bought by a variety of institutional investors in the last quarter, including Two Sigma Investments LP, Rhumbline Advisers, Bank of America Corp DE, Geode Capital Management LLC, Geode Capital Management LLC, SG Americas Securities LLC, Two Sigma Advisers LP and Paloma Partners Management Co. View Insider Buying and Selling for Bellicum Pharmaceuticals. How do I buy shares of Bellicum Pharmaceuticals? Shares of BLCM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Bellicum Pharmaceuticals' stock price today? One share of BLCM stock can currently be purchased for approximately $3.61. How big of a company is Bellicum Pharmaceuticals? Bellicum Pharmaceuticals has a market capitalization of $160.00 million and generates $1.12 million in revenue each year. The biopharmaceutical company earns $-98,040,000.00 in net income (profit) each year or ($2.44) on an earnings per share basis. Bellicum Pharmaceuticals employs 173 workers across the globe. What is Bellicum Pharmaceuticals' official website? The official website for Bellicum Pharmaceuticals is http://www.bellicum.com. How can I contact Bellicum Pharmaceuticals? Bellicum Pharmaceuticals' mailing address is 2130 WEST HOLCOMBE BOULEVARD SUITE 800, HOUSTON TX, 77030. The biopharmaceutical company can be reached via phone at 832-384-1100 or via email at [email protected] MarketBeat Community Rating for Bellicum Pharmaceuticals (NASDAQ BLCM)Community Ranking: 2.8 out of 5 ( )Outperform Votes: 303 (Vote Outperform)Underperform Votes: 235 (Vote Underperform)Total Votes: 538MarketBeat's community ratings are surveys of what our community members think about Bellicum Pharmaceuticals and other stocks. Vote "Outperform" if you believe BLCM will outperform the S&P 500 over the long term. Vote "Underperform" if you believe BLCM will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 3/26/2019 by MarketBeat.com StaffFeatured Article: What are the benefits of a balanced fund?